Top Page
Anteris Technologies Global Corp.
(NASDAQ:AVR)
Anteris Technologies Global Corp. (AVR) vs. SPDR S&P 500 ETF (SPY)
Anteris Technologies Global Corp. Business Overview & Revenue Model
Anteris Technologies Global Corp. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.14M | 2.70M | 2.73M | 3.20M | 5.83M | 5.46M |
| Gross Profit | 1.45M | 1.27M | 876.80K | 298.38K | 1.91M | 3.36M |
| EBITDA | -84.73M | -76.86M | -45.54M | -29.14M | -15.50M | -14.05M |
| Net Income | -84.32M | -76.29M | -46.02M | -30.56M | -17.17M | -11.78M |
Balance Sheet | ||||||
| Total Assets | 19.07M | 80.70M | 30.53M | 15.99M | 21.43M | 9.75M |
| Cash, Cash Equivalents and Short-Term Investments | 9.12M | 70.46M | 21.03M | 9.29M | 15.46M | 3.36M |
| Total Debt | 2.35M | 1.40M | 1.60M | 952.79K | 4.14M | 2.92M |
| Total Liabilities | 15.71M | 18.02M | 11.63M | 6.95M | 10.91M | 7.90M |
| Stockholders Equity | 3.70M | 62.76M | 19.30M | 9.03M | 10.52M | 1.86M |
Cash Flow | ||||||
| Free Cash Flow | -78.41M | -63.51M | -37.03M | -31.08M | -15.02M | -11.30M |
| Operating Cash Flow | -77.51M | -61.24M | -34.63M | -29.42M | -14.44M | -11.08M |
| Investing Cash Flow | -562.57K | -2.28M | -2.58M | -992.57K | -886.07K | 5.99M |
| Financing Cash Flow | 76.57M | 112.83M | 49.34M | 23.27M | 27.42M | 1.46M |
Anteris Technologies Global Corp. Technical Analysis
Anteris Technologies Global Corp. Risk Analysis
Anteris Technologies Global Corp. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $242.93M | 19.33 | 10.53% | ― | 18.90% | 29.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $2.43M | -0.08 | -467.14% | ― | -8.93% | 97.80% | |
42 Neutral | $11.83M | -0.31 | -204.04% | ― | -60.89% | 94.49% | |
41 Neutral | $152.02M | ― | -2462.70% | ― | -21.10% | -18.32% | |
38 Underperform | $7.12M | -1.62 | -69.61% | ― | -11.31% | 47.64% | |
38 Underperform | $145.13M | ― | -422.35% | ― | 21.02% | -200.88% |
Anteris Technologies Global Corp. Corporate Events
On November 3, 2025, Anteris Technologies Global Corp. announced that it received FDA approval to commence its PARADIGM Trial, a global pivotal study of the DurAVR® Transcatheter Heart Valve (THV). This trial, which has already begun in Denmark, marks a significant milestone for the company as it aims to provide robust clinical evidence to support a future Premarket Approval (PMA) submission in the United States and CE Mark approval in Europe. The trial will enroll approximately 1000 patients across the United States, Europe, and Canada to evaluate the safety and effectiveness of the DurAVR® THV compared to commercially available transcatheter aortic valve replacements (TAVRs).
The most recent analyst rating on (AVR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
On October 27, 2025, Anteris Technologies announced the successful enrollment and treatment of the first patients in the global pivotal PARADIGM Trial for the DurAVR® Transcatheter Heart Valve (THV), aimed at patients with severe calcific aortic stenosis. This trial, which is expected to expand across the United States, Europe, and Canada, will provide comparative evidence on the safety and effectiveness of the DurAVR® THV against commercially available transcatheter aortic valve replacements, potentially impacting the company’s market positioning and treatment options for aortic stenosis patients.
The most recent analyst rating on (AVR) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
On October 23, 2025, Anteris Technologies Global Corp. entered into agreements to sell shares of its common stock and CHESS Depositary Interests (CDIs), along with accompanying five-year warrants, to certain investors. The company successfully closed the offering on October 27, 2025, issuing 2,346,936 shares and warrants, and raising approximately US$11.5 million in gross proceeds.
The most recent analyst rating on (AVR) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
On October 23, 2025, Anteris Technologies Global Corp. announced agreements to sell over 5 million shares and accompanying warrants, expected to generate approximately US$25 million in gross proceeds. The offerings, managed by Evolution Capital Pty Ltd, are set to close by the end of October 2025, with the funds likely enhancing Anteris’ market position and supporting its strategic initiatives in the TAVR market.
The most recent analyst rating on (AVR) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
Anteris Technologies Global Corp. will hold its first Annual Meeting of Stockholders on December 3, 2025, with the record date for stockholders set for October 30, 2025. The company has outlined procedures for stockholder proposals to be included in the proxy materials, emphasizing compliance with SEC rules and Delaware law, with a submission deadline of October 25, 2025.
The most recent analyst rating on (AVR) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
On October 15, 2025, Anteris Technologies Global Corp. announced it received its first European regulatory clearance from the Danish Medicines Agency to initiate the DurAVR® Transcatheter Heart Valve global pivotal trial, known as the PARADIGM Trial, for patients with severe calcific aortic stenosis. This milestone positions Anteris to expand the trial across the United States, Europe, and Canada, with patient recruitment in Denmark expected to begin in the fourth quarter of 2025. The trial aims to assess the safety and effectiveness of the DurAVR® valve compared to commercial TAVR devices, potentially leading to multiple approvals and commercialization opportunities. The announcement marks a significant step in Anteris’s lifecycle, reflecting strong interest from clinicians and the potential to transform care for aortic stenosis patients.
The most recent analyst rating on (AVR) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
On September 29, 2025, Anteris Technologies Global Corp. held a special meeting where stockholders approved the ASX Waiver Proposal, allowing the company to issue new securities without stockholder approval under certain conditions. Additionally, the company provided an update on its PARADIGM Trial, with patient enrollment now expected to commence in the fourth quarter of 2025 following additional information requests from the FDA, demonstrating the company’s ongoing commitment to advancing its heart valve technology globally.
The most recent analyst rating on (AVR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
On September 19, 2025, Anteris Technologies Global Corp. announced the adjournment of its Special Meeting of Stockholders due to a lack of quorum. The meeting, initially held virtually on September 18, 2025, was rescheduled to September 29, 2025, to allow more time for stockholders to vote on proposals. The company’s Board of Directors strongly recommends voting in favor of the proposals outlined in the Proxy Statement, which was filed with the SEC on August 18, 2025.
The most recent analyst rating on (AVR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
On September 11, 2025, Anteris Technologies Global Corp. announced the postponement of its Special Meeting of Stockholders to September 18, 2025, to allow additional time for stockholders to vote and ensure broader participation. The company’s board unanimously recommends voting in favor of the proposals in the Proxy Statement, and the record date remains unchanged. This decision reflects Anteris’ commitment to engaging its stakeholders effectively and may influence its strategic direction depending on the outcomes of the stockholder votes.
The most recent analyst rating on (AVR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
On September 4, 2025, Anteris Technologies Global Corp. announced the postponement of its Special Meeting of Stockholders, originally scheduled for September 4, to September 11, 2025. The delay aims to provide stockholders additional time to vote, facilitating broader participation. The company’s Board of Directors recommends voting in favor of the proposals in the Proxy Statement filed with the SEC on August 18, 2025.
The most recent analyst rating on (AVR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
Anteris Technologies Global Corp. is a global structural heart company focused on developing and commercializing innovative medical devices to restore healthy heart function, with a significant presence in Australia and the USA. In its latest earnings report for the second quarter of 2025, Anteris highlighted significant progress in its clinical development and strategic initiatives. The company reported that 130 patients have been implanted with its DurAVR® Transcatheter Heart Valve (THV) since the start of clinical development, with 21 patients treated in the second quarter alone. Notably, Anteris achieved a world-first ‘double DurAVR®’ implant, marking a significant milestone in its clinical advancements. The company is also preparing for the global PARADIGM Trial, having qualified 79 clinical sites and hosted global investigator meetings to align operational activities. Financially, Anteris reported net operating cash outflows of $41.0 million for the first half of 2025, reflecting increased clinical and manufacturing activities. The company held $28.4 million in cash and cash equivalents as of June 30, 2025. Looking ahead, Anteris remains focused on advancing its clinical and commercial objectives, supported by recent strategic board appointments and ongoing engagement with regulatory bodies.